Pharma Journalist -

Takeda announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the…
Read More...

GSK plc and Wave Life Sciences Ltd. a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced a…
Read More...

Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of…
Read More...

Pasithea Therapeutics Corp. a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, announced…
Read More...

Merck, known as MSD outside of the United States and Canada, is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago…
Read More...

CSL Limited announced that its subsidiary, CSL Seqirus, finalized its global collaboration and license agreement with Arcturus Therapeutics Holdings Inc (“Arcturus Therapeutics”;…
Read More...

SAE Media Group reports: The brochure is available to download for the 4th Annual AI in Drug Discovery Conference in London. SAE Media Group is proud to present the return of the AI…
Read More...

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. ("Nitrase"), a biopharmaceutical company…
Read More...

Kite, a Gilead Company and Arcellx, Inc. announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the…
Read More...

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced that Health Canada has approved Empaveli™ (pegcetacoplan), a complement inhibitor, for the…
Read More...